The complete plan to build India's first AI-powered, doctor-led GLP-1 weight loss platform.
The Opportunity
On March 20, 2026, the semaglutide patent expired in India. Within 24 hours, 10+ Indian pharma companies launched generic versions. Prices collapsed from ₹10,000+/month to as low as ₹1,290/month. This is India's GLP-1 moment — the equivalent of what created Medvi in the US.
Medvi (USA) did $401M in year one with $20,000 and two employees. Built entirely with AI tools. The playbook: find a commoditized drug with massive demand, outsource everything regulated, use AI for everything else, and pour money into customer acquisition.
India's version is different — and in some ways better. No compounding gray area. Generics are fully legal, permanently. The regulatory risk that could kill Medvi overnight doesn't exist here.
Matthew Gallagher, a 41-year-old entrepreneur from Los Angeles, launched Medvi in September 2024.
A telehealth storefront for compounded GLP-1 drugs. AI writes the code, generates the ads, handles customer service. Doctors and pharmacy fulfillment are outsourced. The entire company is a routing layer between patients who want weight loss drugs and the healthcare infrastructure that already exists.
His AI stack: ChatGPT, Claude, Grok for code + copy. Midjourney + Runway for ad creatives. ElevenLabs for voice. Custom AI agents connecting all systems. AI chatbot handling 100% of customer service.
Medvi's risks (that Zelta doesn't have): FDA can shut down compounded semaglutide any day. Accused of 800+ ads with AI-generated fake doctors. FDA warning letter received February 2026. No moat.
The India Landscape
| Date | Event |
|---|---|
| 2017 | Novo Nordisk launches Rybelsus (oral semaglutide for diabetes) |
| Mar 2025 | Eli Lilly launches Mounjaro (tirzepatide) — first mover for obesity |
| Apr 2025 | Eli Lilly + Cipla launch Yurpeak via licensing deal |
| Dec 2025 | Novo Nordisk launches Ozempic at ₹8,800–11,175/month |
| Dec 2025 | Novo Nordisk + Emcure launch Poviztra for tier 2/3 reach |
| Mar 10, 2026 | DCGI advisory — specialist-only prescriptions, 49 entities audited |
| Mar 20, 2026 | Semaglutide patent expires in India |
| Mar 21, 2026 | 10+ pharma companies launch generic semaglutide on day one |
| Apr 2026 | Generic price war underway. This is where we enter. |
Branded drugs: Ozempic at ₹8,800–11,175/month. Wegovy (Poviztra) at ₹10,850–16,400. Mounjaro/Yurpeak at ₹12,000–16,000. Rybelsus (oral) at ₹3,000–5,000.
Generic semaglutide (post March 2026): Sun Pharma multi-dose vial at ₹1,290. Glenmark vial + pen at ₹1,300–1,760. Alkem pre-filled pen at ₹1,800. Zydus reusable pen at ₹2,200. Lupin/Zydus Semavic at ₹3,999. Dr. Reddy's disposable pen at ₹4,200.
The arbitrage: A treatment that cost ₹10,000+/month is now available starting at ₹1,290/month. That's a 50–90% price drop. Zelta sits in between — ₹3,999–4,999/month all-inclusive — offering convenience and legitimacy above raw generic pricing, at 50–65% below branded.
1 in 3 Indian adults has a high BMI. By 2030, 404 million Indians will have high BMI (World Obesity Atlas 2025). 101 million people living with Type 2 diabetes. India ranks 2nd globally in overweight/obese children. GLP-1 drug sales grew 115% in 2025, before generics launched.
India's GLP-1 market: ₹1,000–1,200 crore in 2025, projected ₹4,500–5,000 crore by 2030 (CARE Ratings — 5x growth). Nomura projects the addressable market at ₹12,000 crore ($1.4B). Current penetration is near zero. 8% of Indian adults are clinically obese — ~80 million people, and growing.
"Wegovy ya Ozempic hai kya?" has become a daily refrain at neighbourhood chemists (Forbes India, Apr 2026). Pharmacists across Gurugram, Bangalore, Ahmedabad selling without prescriptions. Social media flooded with people buying semaglutide without prescriptions. Google search volume at all-time highs.
Telemedicine Practice Guidelines (TPG 2020): Only registered medical practitioners can prescribe. First consultations for Schedule H drugs (including GLP-1) require video. Follow-ups can be audio/text. Mandatory consent and full documentation.
DCGI Specialist-Only Mandate (March 10, 2026): Semaglutide can ONLY be prescribed by endocrinologists, internal medicine specialists, or cardiologists. NOT general physicians. Surrogate advertising banned. 49 entities audited. Non-compliance means license cancellation, fines, criminal prosecution.
This is actually Zelta's moat. Random pharmacies and fly-by-night apps can't replicate a network of verified specialists doing video consults. When enforcement tightens, Zelta is the compliant player that survives.
E-Pharmacy: No dedicated law yet (draft rules from 2018 pending). Tata 1mg, PharmEasy, Apollo all operate at massive scale — model is proven. A legitimate platform with proper specialist consultations is above the current market standard.
Advertising: Cannot claim "cure" for obesity. Health claims must be substantiated. Safe: "Doctor-prescribed treatment", "specialist-led weight management", "clinically proven GLP-1 therapy". Dangerous: "Lose 20kg guaranteed", "Ozempic alternative", "No prescription needed".
HealthifyRx — Direct competitor. Well-funded, strong brand, but premium/coaching-heavy with complex onboarding.
MantraFit — Small GLP-1 + nutrition player. Personalized but limited reach.
Mosaic Wellness (Man Matters / BeBodywise) — $40M revenue, 366 employees. NOT in GLP-1 yet. Adjacent, could enter.
Tata 1mg, PharmEasy, Apollo — They sell the drug but aren't specialized platforms. Generic pharmacies, not GLP-1 brands.
Practo — Infrastructure/marketplace. Patients ask about semaglutide, but no control over doctor quality.
Critical gap: There is NO dedicated, AI-first, specialist-led GLP-1 telehealth platform in India. The market is wide open.
Business Model
A technology platform that connects patients with specialist doctors for GLP-1 weight loss treatment and delivers medication to their door. We are a routing layer — not a pharmacy, not a clinic, not a drug company.
We never touch the drug. We never employ the doctors full-time. We never run a pharmacy. We are the technology layer that makes the entire experience seamless.
| Layer | Who Handles It | Zelta's Role |
|---|---|---|
| Customer acquisition | AI-generated ads, WhatsApp, organic | We own this entirely |
| Patient intake | Online health assessment on zelta.in | We built this |
| Doctor consultation | Panel of specialists | We recruit, schedule, manage |
| Prescription | Doctor issues e-prescription | Routed through our platform |
| Pharmacy fulfillment | Licensed partner pharmacy | We route prescription to partner |
| Delivery | Cold-chain courier | Partner handles, we track |
| Ongoing support | AI chatbot + monthly follow-ups | We manage |
| Item | Patient Pays | Our Cost | Margin |
|---|---|---|---|
| Doctor consultation | ₹499 | ₹400–800 | Break-even (funnel entry) |
| Monthly medication | Bundled | ₹1,290–2,200 | From plan price |
| Delivery | Free | ₹100–200 | Bundled |
| AI support + follow-ups | Bundled | Near zero | Pure margin |
| Monthly plan | ₹3,999–4,999 | ~₹2,000–2,500 | 40–55% |
Essential — ₹3,999/month. Specialist video consult (first month) + generic semaglutide + delivery + WhatsApp support + monthly audio follow-up.
Premium — ₹5,999/month. Everything in Essential + nutritionist consultation + personalized meal plan + CGM add-on option.
Complete — ₹8,999/month. Everything in Premium + weekly coaching calls + priority doctor access + home blood work.
Start with Essential only. Add tiers as you learn what patients want.
Average plan price ₹4,499/month. Drug + delivery ₹1,800. Doctor cost (amortized) ₹400. Platform/tech ₹100. Gross profit per patient: ₹2,199/month (~49%). Target CAC ₹1,000–2,000. Average lifetime 6–12 months. LTV: ₹13,000–26,000. LTV:CAC ratio: 6.5–26x.
The Patient Journey
Step 1: Discovery. Patient sees a Meta ad, Google result, YouTube ad, or WhatsApp message. "Doctor-prescribed GLP-1 weight loss. Delivered to your door. Starting ₹3,999/month."
Step 2: Assessment (2 minutes). Patient lands on zelta.in, takes a free BMI assessment. Height, weight, age, gender, medical history, current medications, weight loss goal, allergies.
Step 3: Eligibility. Instant result: eligible or not. If eligible, book specialist consultation.
Step 4: Book Consultation (₹499). Pick a time slot. Pay via Razorpay. Confirmation on WhatsApp + email with video call link.
Step 5: Video Consultation (15 min). Licensed endocrinologist reviews assessment, discusses eligibility, outcomes, side effects, dosage plan. If eligible, issues digitally signed e-prescription.
Step 6: Prescription routed. E-prescription auto-sent to partner pharmacy. Patient selects plan. Payment via Razorpay subscription.
Step 7: Delivered. Generic semaglutide injection dispatched (cold-chain, 2–8°C). 3–5 days to door. Includes medication, swabs, instructions, dosage card.
Step 8: Treatment begins. Weekly self-injection. AI chatbot sends WhatsApp reminders, tracks side effects, answers questions. Weekly weight logging.
Step 9: Monthly follow-up. Audio call with the same doctor. Progress review, dosage adjustments, refill prescription. Next month ships automatically.
Step 10: Ongoing. Auto-refill every month. 6–18 months typical. Pause, cancel, or switch tiers anytime.
Customer Acquisition
India has 350M+ Instagram users — urban, affluent, health-conscious. Exactly our target. Creative: pricing comparisons, doctor credibility, "how it works" carousels, video testimonials. Formats: Reels, Stories, Click-to-WhatsApp (highest converting for India). Cities: Mumbai, Delhi-NCR, Bangalore, Hyderabad, Pune, Chennai. Budget: ₹500/day → ₹5,000/day. Target CAC: ₹1,000–1,500.
Click-to-WhatsApp flow: Ad → WhatsApp opens → AI chatbot qualifies → books consultation → sends payment link. India's killer channel. Medvi doesn't have this.
High-intent keywords: "Ozempic India price", "semaglutide generic India", "weight loss injection India", "GLP-1 online consultation India". These searches are exploding post-patent expiry. First mover wins.
Short pre-roll (15 sec). Longer educational content (5–10 min) for SEO and trust. Target health/fitness/diet viewers.
WhatsApp broadcast lists, weekly health tips, referral program ("Refer a friend, ₹500 off"). Health/fitness micro-influencers. Doctor influencers. Blog content for organic search.
✅ "Doctor-prescribed GLP-1 weight management"
✅ "Specialist-led treatment, delivered to your door"
✅ "Starting ₹3,999/month, all-inclusive"
✅ "Clinically proven medications prescribed by endocrinologists"
❌ "Lose 20kg guaranteed"
❌ "Ozempic alternative"
❌ "No prescription needed"
❌ AI-generated fake doctors
❌ Before/after without consent
❌ Claims of "curing" obesity
Operations
Website code: ChatGPT/Claude/Cursor. Ad creatives: Midjourney/Flux for images, Runway/Kling for video. Customer service: AI chatbot via WhatsApp API. Voice: ElevenLabs (Hindi + English). Email campaigns: AI-generated. Patient reminders: automated. Analytics: custom dashboards. Content: AI-generated, human-reviewed.
Panel of 2–3 specialists initially. Each works 1–2 hours/day (evening slots). At 4 patients/hour = 120–240 consults/month per doctor. 3 doctors = 360–720 consults/month capacity. Scale by adding doctors. Zelta handles scheduling, intake, payment, follow-up — doctor just does the consult.
Partner pharmacy receives e-prescription via platform. Stocks multiple generic brands for supply security. Cold-chain packaging and temperature-controlled courier. Zelta tracks delivery and confirms receipt.
Trust & Positioning
The Indian GLP-1 market right now is the Wild West. Chemists selling without prescriptions. Random clinics dispensing like candy. People self-medicating from social media. DCGI actively cracking down. No one platform that patients and doctors both trust.
Zelta's positioning: "The only platform where an actual endocrinologist prescribes your GLP-1 medication via video consultation, legally, with proper monitoring."
When the regulatory crackdown intensifies (and it will), the cowboys die and we're the last one standing. Compliance is the moat.
"Every prescription by a verified Endocrinologist." Real doctor names, photos, registration numbers. "DCGI compliant. Schedule H. Prescription-only." Licensed pharmacy partner. Cold-chain verified delivery. Data protected under DPDP Act 2023. Monthly doctor follow-ups included. Entity details, GST number in footer.
Not a pharmacy. Not a wellness clinic. Not a weight loss program. Not a marketplace. We are a specialist-led, technology-powered prescription platform for medical weight management.
Growth Phases
Goal: Get everything set up. First 50 patients. Buy domains, build MVP website, recruit 2–3 specialists, sign pharmacy partner, legal opinion, set up Razorpay/WhatsApp/Meta. Run first ads at ₹500/day. Manually handle everything. Learn what breaks.
Milestone: 50 paying patients, first prescriptions issued, first deliveries completed.
Goal: Prove the funnel. 500 active patients. Automate chatbot, scheduling, prescription routing. Scale ads to ₹2,000–5,000/day. Add Google Search. Collect testimonials. Iterate on pricing and creatives.
Milestone: 500 active patients, ₹20 lakh MRR, clear CAC and LTV metrics.
Goal: 3,000 active patients. Scale Meta ads to ₹10,000–20,000/day. YouTube + influencer campaigns. 5–8 doctors. Second pharmacy partner. Referral program. Organic content engine. Expand beyond 6 metros.
Milestone: 3,000 active patients, ₹1.2 crore MRR.
Goal: Same machine, new drug categories. Erectile dysfunction (Man Matters proved demand, Medvi hit 50K ED customers month one). Hair loss (₹5,000+ crore market). Diabetes management (101M diabetics). PCOS (1 in 5 Indian women). Rx skincare. Each vertical uses the same infrastructure.
Milestone: 15,000 active patients across verticals, ₹6 crore MRR.
Financial Projections
| Month | Patients | MRR | Notes |
|---|---|---|---|
| 1 | 50 | ₹2 lakh | Manual ops, testing |
| 2 | 150 | ₹6 lakh | Funnel validated |
| 3 | 500 | ₹20 lakh | Ads scaling |
| 4 | 1,000 | ₹40 lakh | Google + influencers |
| 5 | 2,000 | ₹80 lakh | Referrals kick in |
| 6 | 3,000 | ₹1.2 crore | Second vertical |
| 7–9 | 5,000–8,000 | ₹2–3.2 crore | Multi-vertical |
| 10–12 | 10,000–15,000 | ₹4–6 crore | Full scale |
| Year 1 Total | ₹20–40 crore | ||
Key assumptions: ₹4,000/month average. 10–15% monthly churn. ₹1,000–1,500 CAC. 45–55% gross margin. 20–30% net margin at scale.
India's digital ad costs are 5–10x cheaper than the US. If acquisition scales like Medvi's: 50,000 active patients by end of Year 1. ₹20 crore/month MRR. ₹240 crore ARR (~$28M).
Risks & Mitigation
| Risk | Mitigation | |
|---|---|---|
| DCGI tightens enforcement | 🟡 | Already compliant. Tighter enforcement kills competitors, helps us. |
| HealthifyRx or Mosaic competes | 🟡 | Speed + affordability + AI-lean ops is our edge. |
| 1mg/PharmEasy launch GLP-1 vertical | 🟡 | Platforms, not brands. We build the specialized brand first. |
| Generic supply issues | 🟢 | 10+ manufacturers. Multi-source. |
| Patient safety incident | 🔴 | Strict screening, specialist-only, regular follow-ups, insurance. |
| Price war | 🟡 | Margin is on convenience + trust, not the drug. |
| Telehealth GLP-1 ban | 🔴 | Government-endorsed post-COVID. Unlikely. Affects entire industry. |
| Negative GLP-1 media | 🟡 | "This is why you need a specialist." Drives patients to us. |
Zelta vs Medvi
| Factor | Medvi (USA) | Zelta (India) |
|---|---|---|
| Drug source | Compounded (gray area) | Generic (legal forever) |
| Regulatory risk | 🔴 FDA can shut it down | 🟢 Generics permanent |
| Price arbitrage | $1,000 → $179 (82%) | ₹10,000 → ₹3,999 (60%) |
| Doctors | Any licensed doc | Specialist-only (DCGI) |
| Ad costs | $50–150 CAC | ₹1,000–1,500 ($12–18) |
| Market | 138M obese (42%) | 400M+ high BMI by 2030 |
| Payment | Credit card / insurance | UPI (instant) |
| Key channel | Meta + website | Meta + WhatsApp (500M+) |
| Language | English only | Hindi + English + regional |
| Moat | 🔴 None | 🟡 Low but durable |
| Fake doctors | 🔴 800+ fake ads | ✅ Real from day one |
Startup Costs
| Item | Cost | Notes |
|---|---|---|
| Domains (3) | ₹5,000 | zelta.in + .co + .health |
| Company registration | ₹0 | Using Upsurge LLP |
| Website + platform | ₹0–10,000 | AI-built. Cloudflare Pages (free) |
| Doctor retainer | ₹0 upfront | Per-consult (₹400–800) |
| Pharmacy partnership | ₹0 | Revenue-share model |
| AI tools (monthly) | ₹5,000–10,000 | ChatGPT Pro, Midjourney, ElevenLabs |
| WhatsApp API | ₹5,000–15,000/mo | Wati / Interakt / AiSensy |
| Ad spend (Month 1) | ₹2–5 lakh | Meta + Google to test funnel |
| Legal | ₹15,000–25,000 | One-time, health-tech lawyer |
| Razorpay | ₹0 | 2% transaction fees only |
| Total to launch | ₹3–6 lakh | ($3,500–7,000) |
The Team
| Person | Role | Responsibilities |
|---|---|---|
| Sowmay | Product & Website | Website, product strategy, direction |
| Nikhil & Ankit | Ops & Infra | Domains, Razorpay, Meta, accounts |
| Nikhil | Platform Setup | Ad accounts, Practo, WhatsApp, legal |
| Aisurya | Brand & Creative | Social handles, ad ideas, content |
| Kuber | Growth & Ads | Campaigns, performance tracking |
| Ravi & Naksh | Medical Ops | Doctors, pharmacy, compliance |
The semaglutide patent expired 2 weeks ago. 10+ generic manufacturers launched. Prices crashed 50–90%. 400 million Indians will be overweight by 2030. Chemists are selling without prescriptions. DCGI is cracking down. There is no dedicated, compliant, AI-first GLP-1 telehealth platform in India.
Zelta fills that gap. Doctor-prescribed. Specialist-led. Delivered to your door. ₹3,999/month. AI-powered operations. Two-person energy, billion-rupee scale.
The window is open. The time is now.